Nevertheless, further studies are needed to elucidate the function of ADAM17 in mediating PARPi resistance mechanisms in ovarian cancer therapy, in order to identify suitable therapy formats including combinatorial treatments to overcome PARPi resistance in this devastating disease. This evidence concerns the gene ADAM17 and ovarian cancer.